Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229950 | 0.90 | DRD4 (0.59) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL5695486 | 0.89 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL1877824 | 0.89 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL352001 | 0.89 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL351719 | 0.82 | HRH3 (0.64) | DRD4HRH3ALDH1A1LTA4H | |
| SCHEMBL24200050 | 0.81 | HRH3 (0.62) | DRD4HRH3ALDH1A1LTA4H | |
| SCHEMBL17803030 | 0.80 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL21553759 | 0.80 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL7371617 | 0.79 | DRD4 (0.76) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL7368320 | 0.79 | DRD4 (0.59) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648190-B2 | Process for producing 2-hydroxymethylmorpholine salt | DAISO CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| EP-2388252-B1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2388252-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | Daiso Co., Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-8040010-B2 | Permanent magnet type generator and hybrid vehicle using the same | HITACHI, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | THOP1, AVPR2, HPD | DRD4 271/4885DRD2 200/4885DRD3 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.